Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant (SAR439859) in Japanese women with advanced breast cancer
NCT03816839Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amcenestrant in breast cancer, sponsored by Sanofi. Primary endpoint: Dose Limiting Toxicities. Started Mar 2019; status: terminated.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03816839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816839.